Science & Innovation

Avesthagen is a multidisciplinary company that has built integrated capabilities across most areas of biological sciences. Avesthagen looks to deliver personalized healthcare through convergence of food, pharma and population genetics. Avesthagen is offering this expertise in a wide range of areas as "Early Research" which encompasses all upstream processes ensuring efficient product development. 

More and more companies today seek access to new technologies in research and high throughput capabilities without having to invest in additional capital, human and/or material. Companies that have core competencies in mid-stream and down-stream processes in product development will find Avesthagen's Early Research capabilities highly rewarding. Scientific Innovation and Early Research at Avesthagen is driven by excellence in fully integrating the competencies in bioinformatics with molecular biology across:

• Genome Analysis

• Transcriptome Analysis

• Metabolome Analysis and Lead Optimization

• Recombinant Protein Expression

We have been an early starter in product co-development in Genome Analysis. For example, we are analyzing the genomes of TB causing bacteria, Mycobacterium tuberculosis, by employing our expertise in genome sequencing and bioinformatic analyses of sequence data.  We are identifying SNPs that indicate the virulence of the disease causing pathogen at an early stage of the infection process. BioMerieux, France is our partner for this work. We are also partnering with Imperial College, London to identify genomic regions that indicate susceptibility to Lupus, a dreaded human disease. Our expertise in genomic SNP detection and analysis forged this partnership with a world-renowned academic institute such as Imperial College, London. 

Our world-class, state-of-the-art facilities include spacious general laboratories, clean rooms, radioisotope lab, high throughput sequencing on ABI 3700, SNP detection and discovery on Sequenom's MassArray^TM and an upcoming cGMP facility among other infrastructure. We have dedicated scientific personnel with both national and international experience in product co-development. 

Our major current partners include bioMerieux, France, (among the top eight in-vitro diagnostic companies worldwide) for identification of virulence markers as a diagnostic tool for Mycobacterium tuberculosis, Sequenom, USA, for validation of genetic markers for breast and lung cancers and diabetes, Cipla, India, for co-development and manufacturing a bouquet of biopharmaceuticals through a joint venture, Nestle, Switzerland, for co-development of medicinal plant based nutraceuticals for degenerative conditions, INTAS, India, for expression of recombinant proteins.